Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 26, 2019; 7(16): 2247-2255
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2247
Published online Aug 26, 2019. doi: 10.12998/wjcc.v7.i16.2247
Table 2 Mean (95% confidence interval) of main biochemical and hematological tests at 3 time points
| Variable [Mean (95%CI)] | At baseline | At wk 4 | At wk 12 | Sig. |
| Serum. ALT (IU/L) | 54.3 (35.49– 73.11) | 19.55 (11.02-28.08) | 17.45 (15.11-19.80) | < 0.05 |
| Serum AST (IU/L) | 50.7 (36.95-64.45) | 24.05 (16.40-31.70) | 19.95 (17.37-22.53) | < 0.05 |
| T. Bilirubin (mg/dl) | 0.66 (0.49-0.82) | 0.53 (0.42-0.64) | 0.55 (0.45-0.65) | No |
| S. Creatinine (mg/dl) | 0.6 (0.52-0.68) | 0.59 (0.51-0.66) | 0.61 (0.54-0.68) | No |
| WBCs (× 10⁹/L) | 7.27 (6.3-8.2) | 7.62 (6.8-8.5) | 7.3 (6.5-8.1) | No |
| Hemoglobin (g/dL) | 12.16 (11.7-12.6) | 11.9 (11.38-12.35) | 11.70 (11.13-12.27) | No |
| Platelets (× 10⁹/L) | 243 (203-283) | 235.5 (200-271) | 247.3 (213-281) | No |
- Citation: El-Shabrawi MH, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases 2019; 7(16): 2247-2255
- URL: https://www.wjgnet.com/2307-8960/full/v7/i16/2247.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i16.2247